Beyond the skin barrier: nanocarrier-based drug delivery with emerging insights into the gut–skin axis and probiotic modulation in atopic dermatitis
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgag100 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Rohit Sharma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Probiotics, Drug Carriers, Drug Delivery Systems. Die Arbeit nennt 182 Literaturangaben.
Abstract (Originalsprache)
Objectives
To summarize recent advances in nanotechnology-based topical drug delivery systems for atopic dermatitis (AD) and highlight their potential to overcome the limitations of conventional topical therapies, particularly poor skin penetration, adverse effects, and inadequate drug concentrations in deeper skin layers.
Methods
The current literature on nanocarrier-based drug delivery for AD was reviewed, with emphasis on liposomes, ethosomes, transferosomes, solid lipid nanoparticles, nanostructured lipid carriers, polymeric nanoparticles, nanoemulsions, cubosomes, micelles, and metal–organic frameworks. Emerging approaches involving the gut–skin axis and microbiome-modulating strategies, including probiotics and postbiotics, were also considered. Key findings AD is a chronic, relapsing inflammatory skin disease marked by intense pruritus, impaired epidermal barrier function, and immune dysregulation. It affects nearly 20% of children and 3%–10% of adults globally, imposing a significant clinical and socioeconomic burden. Current treatment mainly relies on topical therapies; however, their effectiveness is often limited by poor penetration through the stratum corneum. Prolonged use of conventional topical agents is also associated with adverse effects, which may reduce patient adherence and long-term therapeutic success. Nanocarrier systems offer promising solutions by enhancing skin permeability, enabling controlled and targeted drug delivery, and reducing systemic exposure. Emerging evidence also supports combining nanocarrier-based delivery with microbiome-modulating approaches.
Conclusions
Nanotechnology-based delivery systems show considerable potential for improving topical treatment outcomes in AD. However, despite encouraging preclinical results, clinical translation requires standardized manufacturing, detailed safety evaluation, and well-designed clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India.
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Punjab 160062, India.
- Amity Institute of Pharmacy, Amity University, Mohali, Punjab 140306, India.
ORCID-Profile: Rohit Sharma, Thakur Gurjeet Singh, Ashutosh Kumar, Poonam Negi
Zitieren
APA
Sharma, R., Singh, T. G., Kumar, A., & Negi, P. (2026). Beyond the skin barrier: nanocarrier-based drug delivery with emerging insights into the gut–skin axis and probiotic modulation in atopic dermatitis. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag100
Vancouver
Sharma R, Singh TG, Kumar A, Negi P. Beyond the skin barrier: nanocarrier-based drug delivery with emerging insights into the gut–skin axis and probiotic modulation in atopic dermatitis. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag100
BibTeX
@article{Sharma2026,
author = {Sharma, Rohit and Singh, Thakur Gurjeet and Kumar, Ashutosh and Negi, Poonam},
title = {Beyond the skin barrier: nanocarrier-based drug delivery with emerging insights into the gut–skin axis and probiotic modulation in atopic dermatitis},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag100}
}
EUVIMED